WP-0512-003: A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Status	Active
Effective start/end date	4/25/22 → 2/20/23

Grants and Contracts Details